Starting at $495 Retatrutide (Triple-agonist GLP-1/GIP/Glucagon) Investigational triple agonist (GLP-1/GIP/glucagon) being studied for advanced metabolic and weight loss research
Predrag Sikiric decided that the stomach, which can be injured by stress, must logically make its own protective anti-stress compound
Legitimate Research Directions: Some peptides DO have potential and are being properly studied: Thymosin Alpha-1: Immune support (approved in 35+ countries, trials in US) BPC-157: IF proper human trials ever happen LL-37: Antimicrobial applications Others: Many peptides have theoretical promise But ONLY if studied properly: Randomized controlled trials Safety studies FDA approval process Medical supervision The Problem: Most "wellness peptides" will NEVER go through this process because: They can't be patented (no profit incentive) Companies would rather sell in gray market Proper trials cost $100M+ If trials show they DON'T work, the market disappears So we're stuck in limbo: promising animal data, zero human data, aggressive marketing
Implement a first-in-first-out system ensuring older stock gets used before newer purchases
The research identifies a dysfunctional EIF3H/YAP proteolytic axis as a key mediator between cancer-associated adipocytes and drug response
Toughening the surface of the perovskite film or preparing an ion diffusion barrier layer between the perovskite layer and the adjacent CTL makes sense for solving this concern 33,34
